<DOC>
	<DOC>NCT00504556</DOC>
	<brief_summary>This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF). The duration is 3 months of treatment and a 30 day follow-up visit.</brief_summary>
	<brief_title>A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1. Male or female, 18 to 80 years old. 2. Able to provide written informed consent. 3. Persistent nonvalvular AF supported by abnormal electrocardiogram (ECG) 4. A congestive heart failure, hypertension, age â‰¥ 75 years, diabetes, and prior stroke (CHADS2) index score of at least 2 1. Subjects with mitral valve disease or previous valvular heart surgery 2. Known contraindication to any anticoagulant including vitamin K antagonists such as warfarin 3. Known or suspected hereditary or acquired bleeding or coagulation disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Anti-coagulant</keyword>
	<keyword>Non-valvular</keyword>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>Prevention of Blood Clots</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Non-valvular atrial fibrillation</keyword>
</DOC>